# US 11,471,439 B2 · Compositions and methods comprising a combination of serotonergic drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,471,439 B2
- Document ID: US11471439B2
- Status: Granted
- Kind: B2
- Application number: 17/388,252
- Filed: 2021-07-29
- Published: 2021-11-18
- Granted: 2022-10-18
- Earliest claimed: 2017-02-09
- Assignees: Caamtech, Inc.
- Applicants: Caamtech, Inc.
- Inventors: Andrew R. Chadeayne
- Web page: https://patentgrep.com/patent/US11471439B2

## CPC

- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61K 31/48: Ergoline derivatives, e.g. lysergic acid, ergotamine
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure pertains to new compositions and methods comprising a first serotonergic drug and a second serotonergic drug. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, a purified terpene, a purified tryptamine, purified LSD, and/or purified MDMA.

## Claims

### Claim 1

A dosage composition comprising a homogenous mixture of:
a first psilocybin derivative selected from [3-(2-Dimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N,N-dimethyltryptamine, [3-(2-trimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N,N,N-trimethyltryptamine, [3-(2-methylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3-(aminioethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxytryptamine, and their salts; and
a first terpene selected from the group consisting of acetanisole, acetyl cedrene, anisole, bornyl acetate, alpha-bisabolol, borneol, cadinene, cafestol, caffeic acid, camphene, camphor, capsaicin, carene, carotene, carvacrol, carvone, alpha-caryophyllene, beta-caryophyllene, car ophyllene oxide, cedrene, cedrene epoxide, cecanal, cedrol, cembrene, cinnamaldehyde, citronellal, citronellol, cymene, eicosane, elemene, estragole, ethyl cinnamate, ethyl maltol, eucalyptol/1,8-cineole, eudesmol, eugenol, euphol, farnesene, farnesol, fenchone, fenchol, geraniol, geranyl acetate, guaia-1(10),11-diene, guaiacol, guaiol, guaiene, gurjunene, herniarin, hexanaldehyde, hexanoic acid, humulene, ionone, ipsdienol, isoamyl acetate, isoamyl alcohol, isoamyl formate, isoborneol, isomyrcenol, isoprene, isopulegol, isovaleric acid, lavandulol, limonene, gamma-linolenic acid, linalool, longifolene, lycopene, methyl butyrate, 3-mercapto-2-methylpentanal, beta-mercaptoethanol, mercaptoacetic acid, methylbutenol, methyl-2-methylvalerate, methyl thiobutyrate, beta-myrcene, gamma-muurolene, nepetalactone, nerol, nerolidol, neryl acetate, nonanaldehyde, nonanoic acid, ocimene, octanal, octanoic acid, pentyl butyrate, phellandrene, phenylacetaldehyde, phenylacetic acid, phenylethanethiol, phytol, pinene, propanethiol, pristimerin, pulegone, retinol, sabinene, squalene, taxadiene, terpineol, terpine-4-ol, terpinolene, thujone, umbelliferone, undecanal, verdoxan, and valencene;
wherein the dosage composition comprises a molar ratio of between about 100:1 to about 1:100 of the first psilocybin derivative and the first terpene.

### Claim 2 (depends on 1)

The dosage composition of claim 1, further comprising an excipient.

### Claim 3 (depends on 1)

The dosage composition of claim 1, further comprising a monoamine oxidase inhibitor.

### Claim 4 (depends on 1)

The dosage composition of claim 1, wherein the composition comprises a molar ratio of between about 10:1 to about 1:10 of the first psilocybin derivative and the first terpene.

### Claim 5 (depends on 1)

The dosage composition of claim 1, wherein the composition comprises a molar ratio of between about 5:1 to about 1:5 of the first psilocybin derivative and the first terpene.

### Claim 6 (depends on 1)

The dosage composition of claim 1, wherein the composition comprises a molar ratio of between about 50:1 to about 1:50 of the first psilocybin derivative and the first terpene.

### Claim 7 (depends on 1)

The dosage composition of claim 1, wherein the composition comprises a molar ratio of between about 75:1 to about 1:75 of the first psilocybin derivative and the first terpene.

### Claim 8 (depends on 1)

The dosage composition of claim 1, wherein the first psilocybin derivative comprises [3-(2-Dimethylaminoethyl)-1H--indol-4-yl] dihydrogen phosphate.

### Claim 9 (depends on 1)

The dosage composition of claim 1, wherein the first psilocybin derivative comprises 4-hydroxy-N,N-dimethyltryptamine.

### Claim 10 (depends on 1)

The dosage composition of claim 1, wherein the first psilocybin derivative comprises [3-(2-methylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate.

### Claim 11 (depends on 1)

The dosage composition of claim 1, wherein the first psilocybin derivative comprises 4-hydroxy-N-methyltryptamine.

### Claim 12 (depends on 11)

The dosage composition of claim 11, wherein the 4-hydroxy-N-methyltryptarnine is a freebase.

### Claim 13 (depends on 12)

The dosage composition of claim 12, wherein the 4-hydroxy-N-methyl-tryptamine freebase is crystalline.

### Claim 14 (depends on 11)

The dosage composition of claim 11, whereinthe 4-hydroxy-N-rnethyltryptamine is a crystalline salt.

### Claim 15 (depends on 1)

The dosage composition of claim 1, wherein the homogeneous mixture has little or no deviation in chemical composition between different samples taken of the composition.

### Claim 16 (depends on 1)

The dosage composition of claim 1, wherein the first terpene is 80-100% pure.

### Claim 17 (depends on 1)

The dosage composition of claim 1, wherein the first terpene is 90-100% pure.

### Claim 18 (depends on 16)

The dosage composition of claim 16, wherein the composition homogeneous mixture has little or no deviation in chemical composition between different samples taken of the composition, and wherein the chemical composition is determined by chromatography and/or spectrometry.

### Claim 19 (depends on 1)

The dosage composition of claim 1, wherein the first terpene is selected from the group consisting of bornyl acetate, alpha-bisabolol, borneol, camphene, camphor, carene, beta-caryophyllene, cedrene, cymene, elemene, eucalyptol, eudesmol, farnesene, fenchol, geraniol, guaiacol, humulene, isoborneol, limonene, linalool, beta-rnyrcene, nerolidol, ocimene, phellandrene, phytol, pinene, pulegone, sabinene, terpineol, terpinolene, and valencene.

### Claim 20 (depends on 1)

The dosage composition of claim 1, wherein the first psilocybin derivative and the first terpene are present in pureposefully engineered and unnaturally occuring molar ratios.

### Claim 21 (depends on 1)

The dosage composition of claim 1, wherein the dosage composition has less than about 10% deviation between samples taken from a batch of the dosage composition.

### Claim 22 (depends on 1)

The dosage composition of claim 1, wherein the dosage composition comprises 0-5 mass percent of water.
